OMERS ADMINISTRATION Corp Boosts Stake in Pfizer Inc. (NYSE:PFE)

OMERS ADMINISTRATION Corp grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 241,680 shares of the biopharmaceutical company's stock after purchasing an additional 18,448 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Pfizer were worth $6,412,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Pfizer in the 4th quarter worth about $2,328,986,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Raymond James Financial Inc. bought a new position in Pfizer during the fourth quarter worth $274,694,000. Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. increased its stake in Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after purchasing an additional 5,153,257 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Up 1.0%

NYSE PFE traded up $0.23 during mid-day trading on Friday, reaching $22.83. The stock had a trading volume of 37,727,922 shares, compared to its average volume of 40,863,377. The stock has a market cap of $129.77 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a fifty day moving average price of $23.72 and a 200 day moving average price of $25.40.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the business posted $0.82 earnings per share. The business's revenue for the quarter was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's dividend payout ratio is currently 124.64%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.